Global Information
회사소개 | 문의 | 위시리스트

세계의 베체트병 치료제 시장(2019-2023년)

Behcet´s Disease Therapeutics Market by Product and Geography - Global Forecast and Analysis 2019-2023

리서치사 TechNavio (Infiniti Research Ltd.)
발행일 2019년 08월 상품 코드 909630
페이지 정보 영문 150 Pages
가격
US $ 2,500 ₩ 2,952,000 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,000 ₩ 3,542,000 PDF by E-mail (5-user License) help
동일 사업장 내 5명까지 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,723,000 PDF by E-mail (Enterprise License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 5,904,000 PDF by E-mail (Global License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다. 또한 해당 라이선스는 보고서 컨텐츠의 15% 이내로 외부용 문서에 인용 게재가 허용됩니다(예:프레스릴리스, 마케팅 자료, 백서 등).


세계의 베체트병 치료제 시장(2019-2023년) Behcet´s Disease Therapeutics Market by Product and Geography - Global Forecast and Analysis 2019-2023
발행일 : 2019년 08월 페이지 정보 : 영문 150 Pages

세계의 베체트병 치료제 시장은 의약품의 적응외 대량 사용, 특별약 지정, 희귀질환에 대한 연구 자금 증가 등이 성장 촉진요인이 되어 예측기간 중 6% 이상의 CAGR로 확대될 전망입니다. 그러나 진단의 어려움, 소분자 기반 약물의 부작용, 특발성 질환의 성질 등의 요인이 예측기간 중 베체트병 치료제 산업의 성장을 저해할 가능성이 있습니다.

세계의 베체트병 치료제(Behcet's Disease Therapeutics) 시장에 대해 조사 분석했으며, 시장 규모 및 성장률, 시장 동향, 시장 성장 촉진요인과 과제, 시장 기회, 주요 벤더 등에 대한 체계적인 정보를 제공합니다.

목차

제1장 주요 요약

제2장 조사 범위

  • 서론 1
  • 서론 2
  • 달러 통화 환산율

제3장 시장 상황

  • 시장 생태계
  • 시장 특징
  • 시장 세분화 분석

제4장 시장 규모

  • 시장 정의
  • 시장 규모(2018년)
  • 시장 규모 및 예측(2018-2023년)

제5장 Five Forces 분석

  • 구매자의 협상력
  • 공급업체의 협상력
  • 신규 참여업체의 위협
  • 대체품의 위협
  • 경쟁사의 위협
  • 시장 상황

제6장 시장 세분화 : 제품별

  • 시장 세분화 : 제품별
  • 제품별 비교 : 시장 규모 및 예측(2018-2023년)
  • 소분자
  • 생물제제
  • 시장 기회 : 제품별

제7장 고객 상황

제8장 지역별 상황

  • 지역별 세분화
  • 지역별 비교 : 시장 규모 및 예측(2018-2023년)
  • 북미
  • 유럽
  • 아시아
  • 기타 지역
  • 주요 국가
  • 시장 기회

제9장 의사결정 체계

제10장 성장 촉진요인과 과제

  • 시장 성장 촉진요인
  • 시장 과제

제11장 시장 동향

제12장 벤더 상황

  • 개요
  • 창조적 파괴 상황
  • 경쟁 시나리오

제13장 벤더 분석

  • 대상 벤더
  • 벤더 분류
  • 벤더의 시장 포지셔닝
  • AbbVie Inc.
  • Amgen Inc.
  • Celgene Corp.
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Co. Ltd.

제14장 부록

  • 조사 방법
  • 약어 리스트
  • 벤더의 시장 포지셔닝 정의

제15장 TechNavio 소개

KSM 19.09.06

About this market

Technavio's Behcet's disease therapeutics market analysis considers sales from both small molecules and biologics. Our analysis also considers the sales of Behcet's disease therapeutics in Asia, Europe, North America, and ROW. In 2018, the small molecules segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as cost-effectiveness and strong penetration will play a significant role in the small molecules segment to maintain its market position. Also, our global Behcet's disease therapeutics market report looks at factors such as heavy use of off-label drugs, special drug designations, and increasing research funding for rare diseases. However, difficulty in diagnosis, adverse effects of small molecule-based drugs, and idiopathic nature of the disease may hamper the growth of the Behcet's disease therapeutics industry over the forecast period.

Overview

Increasing research funding for rare diseases

Currently, global Behcet's disease therapeutics market has only two approved drugs for the treatment of the condition. Although the condition is rare, its increasing prevalence is leading to the intense R&D novel therapies by vendors and research institutes for the development of treatment for Behcet's disease. These vendors and institutes rely on grants from organizations that provide research funding. These organizations aim to improve the quality of life of patients' vasculitis and associated diseases and increases awareness about rare diseases among public and medical practitioners. This will lead to the expansion of the global Behcet's disease therapeutics market at a CAGR of over 6% during the forecast period.

The advent of novel therapies

Behcet's disease is also considered to be associated with genetic mutations and autoimmune disorders, for which the market has a huge unmet need. The reason for the growing preference for a novel therapy for the treatment of life-threatening disorders is its curative nature. The huge unmet need has attracted various pharmaceutical companies and academic institutions to invest substantially in the R&D of novel therapies for the treatment of Behcet's disease. Factors such as recent advances in the research of these novel therapies are attracting the companies to start the research on gene therapy for Behcet's disease. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global Behcet's disease therapeutics market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of several major players, the global Behcet's disease therapeutics market is fragmented. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading Behcet's disease therapeutics manufacturers. These include AbbVie Inc., Amgen Inc., Celgene Corp., Eisai Co. Ltd., F. Hoffmann-La Roche Ltd., Johnson & Johnson Services Inc., Mylan NV, Novartis AG, Pfizer Inc., Takeda Pharmaceutical Co. Ltd.

Also, Behcet's disease therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Small molecules - Market size and forecast 2018-2023
  • Biologics - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie Inc.
  • Amgen Inc.
  • Celgene Corp.
  • Eisai Co. Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson Services Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Co. Ltd.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

LIST OF EXHIBITS:

  • Exhibit 01: Product overview
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Product - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by product
  • Exhibit 20: Small molecules - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Small molecules - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Biologics - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Biologics - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Market opportunity by product
  • Exhibit 25: Customer landscape
  • Exhibit 26: Market share by geography 2018-2023 (%)
  • Exhibit 27: Geographic comparison
  • Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 30: Top 3 countries in North America
  • Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 33: Top 3 countries in Europe
  • Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 36: Top 3 countries in Asia
  • Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 39: Top 3 countries in ROW
  • Exhibit 40: Key leading countries
  • Exhibit 41: Market opportunity
  • Exhibit 42: Drug designations
  • Exhibit 43: Side effects of small molecule-based drugs used for treatment of Behcet's disease
  • Exhibit 44: Impact of drivers and challenges
  • Exhibit 45: Vendor landscape
  • Exhibit 46: Landscape disruption
  • Exhibit 47: Vendors covered
  • Exhibit 48: Vendor classification
  • Exhibit 49: Market positioning of vendors
  • Exhibit 50: AbbVie Inc. - Vendor overview
  • Exhibit 51: AbbVie Inc. - Business segments
  • Exhibit 52: AbbVie Inc. - Organizational developments
  • Exhibit 53: AbbVie Inc. - Geographic focus
  • Exhibit 54: AbbVie Inc. - Key offerings
  • Exhibit 55: AbbVie Inc. - Key customers
  • Exhibit 56: Amgen Inc. - Vendor overview
  • Exhibit 57: Amgen Inc. - Product segments
  • Exhibit 58: Amgen Inc. - Organizational developments
  • Exhibit 59: Amgen Inc. - Geographic focus
  • Exhibit 60: Amgen Inc. - Key offerings
  • Exhibit 61: Amgen Inc. - Key customers
  • Exhibit 62: Celgene Corp. - Vendor overview
  • Exhibit 63: Celgene Corp. - Business segments
  • Exhibit 64: Celgene Corp. - Organizational developments
  • Exhibit 65: Celgene Corp. - Geographic focus
  • Exhibit 66: Celgene Corp. - Key offerings
  • Exhibit 67: Celgene Corp. - Key customers
  • Exhibit 68: Eisai Co. Ltd. - Vendor overview
  • Exhibit 69: Eisai Co. Ltd. - Business segments
  • Exhibit 70: Eisai Co. Ltd. - Organizational developments
  • Exhibit 71: Eisai Co. Ltd. - Geographic focus
  • Exhibit 72: Eisai Co. Ltd. - Segment focus
  • Exhibit 73: Eisai Co. Ltd. - Key offerings
  • Exhibit 74: Eisai Co. Ltd. - Key customers
  • Exhibit 75: F. Hoffmann-La Roche Ltd. - Vendor overview
  • Exhibit 76: F. Hoffmann-La Roche Ltd. - Business segments
  • Exhibit 77: F. Hoffmann-La Roche Ltd. - Organizational developments
  • Exhibit 78: F. Hoffmann-La Roche Ltd. - Geographic focus
  • Exhibit 79: F. Hoffmann-La Roche Ltd. - Segment focus
  • Exhibit 80: F. Hoffmann-La Roche Ltd. - Key offerings
  • Exhibit 81: F. Hoffmann-La Roche Ltd. - Key customers
  • Exhibit 82: Johnson & Johnson Services, Inc. - Vendor overview
  • Exhibit 83: Johnson & Johnson Services, Inc. - Business segments
  • Exhibit 84: Johnson & Johnson Services, Inc. - Organizational developments
  • Exhibit 85: Johnson & Johnson Services, Inc. - Geographic focus
  • Exhibit 86: Johnson & Johnson Services, Inc. - Segment focus
  • Exhibit 87: Johnson & Johnson Services, Inc. - Key offerings
  • Exhibit 88: Johnson & Johnson Services, Inc. - Key customers
  • Exhibit 89: Mylan NV - Vendor overview
  • Exhibit 90: Mylan NV - Product segments
  • Exhibit 91: Mylan NV - Organizational developments
  • Exhibit 92: Mylan NV - Geographic focus
  • Exhibit 93: Mylan NV - Segment focus
  • Exhibit 94: Mylan NV - Key offerings
  • Exhibit 95: Mylan NV - Key customers
  • Exhibit 96: Novartis AG - Vendor overview
  • Exhibit 97: Novartis AG - Business segments
  • Exhibit 98: Novartis AG - Organizational developments
  • Exhibit 99: Novartis AG - Geographic focus
  • Exhibit 100: Novartis AG - Segment focus
  • Exhibit 101: Novartis AG - Key offerings
  • Exhibit 102: Novartis AG - Key customers
  • Exhibit 103: Pfizer Inc. - Vendor overview
  • Exhibit 104: Pfizer Inc. - Business segments
  • Exhibit 105: Pfizer Inc. - Organizational developments
  • Exhibit 106: Pfizer Inc. - Geographic focus
  • Exhibit 107: Pfizer Inc. - Segment focus
  • Exhibit 108: Pfizer Inc. - Key offerings
  • Exhibit 109: Pfizer Inc. - Key customers
  • Exhibit 110: Takeda Pharmaceutical Co. Ltd. - Vendor overview
  • Exhibit 111: Takeda Pharmaceutical Co. Ltd. - Business segments
  • Exhibit 112: Takeda Pharmaceutical Co. Ltd. - Organizational developments
  • Exhibit 113: Takeda Pharmaceutical Co. Ltd. - Geographic focus
  • Exhibit 114: Takeda Pharmaceutical Co. Ltd. - Key offerings
  • Exhibit 115: Takeda Pharmaceutical Co. Ltd. - Key customers
  • Exhibit 116: Validation techniques employed for market sizing
  • Exhibit 117: Definition of market positioning of vendors
Back to Top
전화 문의
F A Q